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Abstract
Context—Current behavioral measures poorly predict treatment outcome in social anxiety
disorder (SAD). To our knowledge, this is the first study to examine neuroimaging-based
treatment prediction in SAD.
Objective—To measure brain activation in patients with SAD as a biomarker to predict
subsequent response to cognitive behavioral therapy (CBT).
Design—Functional magnetic resonance imaging (fMRI) data were collected prior to CBT
intervention. Changes in clinical status were regressed on brain responses and tested for selectivity
for social stimuli.
Setting—Patients were treated with protocol-based CBT at anxiety disorder programs at Boston
University or Massachusetts General Hospital and underwent neuroimaging data collection at
Massachusetts Institute of Technology.
Patients—Thirty-nine medication-free patients meeting DSM-IV criteria for the generalized
subtype of SAD.
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Interventions—Brain responses to angry vs neutral faces or emotional vs neutral scenes were
examined with fMRI prior to initiation of CBT.
Main Outcome Measures—Whole-brain regression analyses with differential fMRI responses
for angry vs neutral faces and changes in Liebowitz Social Anxiety Scale score as the treatment
outcome measure.
Results—Pretreatment responses significantly predicted subsequent treatment outcome of
patients selectively for social stimuli and particularly in regions of higher-order visual cortex.
Combining the brain measures with information on clinical severity accounted for more than 40%
of the variance in treatment response and substantially exceeded predictions based on clinical
measures at baseline. Prediction success was unaffected by testing for potential confounding
factors such as depression severity at baseline.
Conclusions—The results suggest that brain imaging can provide biomarkers that substantially
improve predictions for the success of cognitive behavioral interventions and more generally
suggest that such biomarkers may offer evidence-based, personalized medicine approaches for
optimally selecting among treatment options for a patient.
Social anxiety disorder (SAD), one of the most common psychiatric conditions in the United
States,1 is a chronic and disabling disorder associated with substantial impairment,
decreased quality of life, and psychiatric comorbidity.2–5 The 2 gold-standard treatments for
SAD are cognitive behavioral therapy (CBT) and pharmacotherapy. Both treatment
modalities are similarly but only moderately effective, with a large proportion of patients
remaining symptomatic after the initial intervention.6–8 Although such treatments are
superior to placebo on average, no reliable predictor of treatment response has been
identified.
Possibly the major reason for the large interindividual differences in treatment
responsiveness are variations within current psychiatric disease categories, which are present
at all levels (genetic, neurobiological, and phenotypic). This fundamental variability is not
well understood but is likely to be essential for understanding etiologies and enhancing
treatments for these diseases.9 Non-invasive neuroimaging measures may provide important
indices of patient variation (biomarkers or neuromarkers) because psychiatric diseases can
be conceptualized as brain disorders, and brain structure and function reflect both genetic
and environmental influences on current behavior.
Some studies using neuromarkers have reported promising findings that likely captured
meaningful variations across individuals who shared a diagnosis and that could allow for
improved prognosis in patients with a range of behavioral disorders. For instance, in
schizophrenia, neuromarkers have been used to identify individuals at high risk for the
disease, predict onset of psychosis in high-risk individuals,10 and predict treatment
outcome.11 In depression, neuromarkers have predicted recovery from the disease 8 months
later12 and CBT or drug treatment response.13–15 Furthermore, neuromarkers have been
used to predict the likelihood of relapse in drug addiction.16 Finally, neuromarkers have also
been successfully applied outside the domain of psychiatry. In dyslexia, evoked-response
potentials measured in newborns17 and prereading children18 with familial risk have
predicted language and reading scores years later. Similar prediction success over multiple
years was reported with functional magnetic resonance imaging (fMRI) in dyslexic
participants.19
Considering the high prevalence of anxiety disorders, surprisingly few studies have thus far
correlated neuroimaging with treatment outcome for this class of disorders. Generalized
anxiety disorder has been studied most extensively in this context20,21 with a focus on
predictions for pharmacological treatment outcome. These outcome predictions for
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generalized anxiety disorder and other anxiety disorders22 were reported primarily for a
priori regions of interest in the amygdala and anterior cingulate cortex.
In the present study, we asked whether fMRI could better predict treatment outcome of CBT
in SAD than current clinical measures alone. To this end, 39 patients with generalized SAD
underwent an fMRI session in which they viewed faces or scenes with either neutral or
negative emotional valence (anger in the case of faces). Given the dissociable
representations of faces and scenes in the extrastriate visual cortex both for neutral and
emotional stimuli,23 this paradigm allowed for assessing the category selectivity of
outcome-predictive brain responses. Based on previous findings using face stimuli with
patients with SAD24,25 and because of the social nature of the disorder, we hypothesized
that stimuli with social content (faces) would be of higher relevance for treatment prediction
than those lacking this content (scenes without people). Further, we expected that brain
regions identified as dysfunctional in prior neuroimaging studies of SAD might provide
predictive information about treatment response. These brain regions include the amygdala
and other limbic brain structures26 and cortical regions in the occipital, temporal, and frontal
lobes, which have been implicated in emotion processing.24,25,27,28
Patients participated in 12 weekly CBT sessions according to a standardized protocol-based
group treatment.29 Measures of social anxiety, obtained prior to and after therapy sessions to
assess treatment-related changes, were correlated with brain-activation data collected at pre-
treatment. Based on findings from previous studies comparing patients with SAD and
controls, we hypothesized that a regression analysis based on the differential signal for
angry vs neutral faces would allow the most successful treatment response prediction. Angry
faces, relative to neutral faces, convey disapproval and are likely to evoke excessive fear
responses and negative cognitions in patients with SAD. Also, means to downregulate these
responses are learned during CBT.
A robust, clinically useful model should predict improvement for any individual prior to
treatment selection. We used cross-validated machine-learning techniques to develop and
test such a prediction model that can predict CBT outcome based on an individual’s brain
activation and score on the Liebowitz Social Anxiety Scale (LSAS).30 We also examined the
specificity of findings by comparing brain activation responses to social stimuli (faces) with
those to nonsocial emotional scene stimuli and how much prediction accuracy is improved
by using brain activation values relative to a standard rating scale, namely initial SAD
severity.
Taken together, to our knowledge, we report the first data on neuromarkers for treatment
responses to CBT in a large sample of patients with SAD. Based on the hypothesis that brain
activation could be a more sensitive measure for revealing interindividual variability in SAD
pathology relevant for treatment response, we expected fMRI-guided predictions of
treatment responsiveness to exceed those based on conventional clinical assessments and
self-reports.
METHODS
SUBJECTS
Outpatients were recruited from 2 recruitment sites, the Center for Anxiety and Related
Disorders at Boston University (n=23) and the Center for Anxiety and Traumatic Stress at
the Massachusetts General Hospital (n=18). Patients gave written informed consent to all
procedures, which were approved by the internal review boards of all 3 sites. Data from all
41 patients with SAD (generalized subtype) who were scanned and who completed the CBT
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study were included in these analyses. Nine additional scanned patients (<20%) dropped out
of treatment early.
Patients were not taking concurrent psychotropic medication for at least 2 weeks prior to the
scan session and CBT initiation. Consistent with an earlier study involving both clinical
sites,31 diagnoses were confirmed at the Massachusetts General Hospital with the Structured
Clinical Interview for DSM-IV32 or at the Center for Anxiety and Related Disorders with
the Anxiety Disorders Interview Schedule for DSM-IV.33 Severity of social anxiety was
measured using the clinician-administered version of the LSAS,30 which was also used as
the dependent variable for analyses. Clinical assessments took place both immediately prior
to and after 12 weekly treatment sessions with group-based CBT (see eAppendix [http://
www.archgenpsychiatry.com] for details of clinical assessments). Neuroimaging data for 1
participant were discarded from analysis because of a suboptimal slice prescription resulting
in incomplete coverage of the most dorsal and ventral portions of the brain. Treatment gain
(LSAS score at pretreatment [LSAS-pre] minus LSAS score at posttreatment [LSAS-
post]=change in LSAS score [LSAS-change]) for 1 participant was more than 3 SDs higher
than the average in our sample. Because of the high sensitivity of regression analyses to
outliers, this participant was also excluded, leaving an overall sample size of 39 patients (14
female; additional information provided in eTable 1).
Unrelated to the objective of this analysis, patients were randomized to receive either
placebo or the antibiotic D-cycloserine prior to 5 of the CBT sessions. D-Cycloserine has
been shown to have a facilitative effect on the outcome of CBT for a variety of anxiety
disorders including SAD.31 In all analyses, the effect of treatment group (D-cycloserine or
placebo) was explicitly accounted for.
STIMULI AND TASK
For the fMRI task (Figure 1), color face images came from the NimStim stimulus set34 and
color images of scenes, from the International Affective Picture System.35 Overall, 5
different types of images were included in the experiment: (1) negative emotional (angry)
faces, (2) neutral faces, (3) negative emotional scenes, (4) neutral scenes, and (5) more
intensively negative emotional scenes. Details on properties and assessments of the stimuli
are in the eAppendix and eTable 2.
During the imaging experiment, stimuli were projected using a Hitachi (CP-X1200 series)
projector and displayed on a rear projection screen that was visible for the subject in a
supine position via a tilted mirror fixed to the head coil. Each of the 5 experimental
conditions consisted of 30 stimuli presented in six 15-second blocks of 6 stimuli. Each
image was presented for 1250 milliseconds, followed by 1250 milliseconds of fixation. The
experimental run started and finished with 1 fixation block, and each full cycle of 5 blocks
(1 for each condition) was separated by 1 fixation block. The whole run comprised 37
blocks: 6 blocks per condition plus 7 blocks of fixation. One of 2 fixed orders of
experimental blocks was used for each participant with 1 block order being the reverse of
the other.
Participants performed a 1-back task while in the scanner. For each stimulation block,
participants had to indicate via button press the repetition of 1 stimulus. Participants
performed at ceiling (mean [SD] correct, 96.1% [0.08]) for this task with little variation
between experimental conditions (P>.10 for all paired t tests).
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IMAGING
Structural and Functional Image Acquisition—Imaging was conducted with a 3-T
Siemens TIM Trio system at the Athinoula A. Martinos Imaging Center at McGovern
Institute for Brain Research, Massachusetts Institute of Technology. A 32-channel birdcage
head coil was used for image acquisition.
One high-resolution structural image was acquired using a T1-weighted 3-dimensional
radio-frequency spoiled gradient-echo magnetization-prepared rapid acquisition with
gradient echo sequence that optimized the contrast for a range of tissue properties. The pulse
sequence was configured as follows: repetition time = 2530 milliseconds, echo time = 3.39
milliseconds, flip angle = 9°, field of view = 256 ×256 mm, one hundred seventy-six 1×1
mm in-plane sagittal slices, and 1 mm thickness. Total scan time for this was approximately
8 minutes.
Functional images were collected using a gradient-echo T2*-weighted sequence (repetition
time=2500 milliseconds, echo time=30 milliseconds, and flip angle=90°). Twenty-seven
contiguous oblique slices (voxel size: 1.7×1.7×4.5 mm) were acquired interleaved; oblique
orientation was defined as a −30° to −40° tilt from a slice parallel to the intercomissural
plane. Sequences included prospective acquisition correction for head motion.36
Data Preprocessing—Data analysis was done using Statistical Parametric Mapping
version 8 (Wellcome Department of Imaging Neuroscience, www.fil.ion.ucl.ac.uk/spm).
The analysis was implemented in Nipype,37 a Python-based framework that permits efficient
batch processing and integration of several neuroimaging analysis packages (http://nipy.org/
nipype).
Functional images from each participant were realigned using a 2-pass procedure to the
mean functional image and coregistered to the anatomical image using a rigid-body
transformation. Structural data were segmented and normalized to Montreal Neurological
Institute space using the Statistical Parametric Mapping unified segmentation algorithm.38 A
Python implementation of the Artifact Detection Tools (http://www.nitrc.org/projects/
artifact_detect) available via Nipype was used to detect outliers (composite volume-to-
volume motion >1 mm and intensity >3 SDs) in the functional time-series data and remove
them from the analysis. On average, only 5.2 (SD, 9.7) time points per subject were
excluded as outliers so that across the 39 subjects, 202 time points (2.3%) were excluded. A
spatial smoothing kernel of 6 mm (full width at half maximum) was applied to the functional
data. The time series in each voxel was high-pass filtered with a cutoff at 1/128 Hz.
Subject-specific first-level analysis was then applied using a general linear model approach.
Regressors for each of the 5 experimental conditions were entered into the design matrix
after convolving with the canonical Statistical Parametric Mapping hemodynamic response
function. Motion parameters and outliers as detected by Artifact Detection Tools were
included in the model as nuisance variables. Beta images modeling the contribution of each
experimental condition were submitted to further analysis for contrasts of interests, in
particular for responses to angry vs neutral faces and emotional vs neutral scenes.
Details of the experimental approach are specified in the eAppendix and eFigure 1. Subject-
specific contrast images were submitted to random-effects second-level statistics. We
entered the contrast images into an analysis of covariance regressing LSAS-change onto
brain responses, controlling for the effect of initial severity (LSAS-pre) and treatment group
(D-cycloserine vs placebo). The treatment group was controlled through an interaction with
both LSAS-change and LSAS-pre using a design matrix with separate columns for D-
cycloserine and placebo (eFigure 2) and a contrast computing the mean LSAS-change across
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these 2 patient groups. A voxelwise threshold of P<.001 plus a topological correction
procedure39 was applied to account for false positives and limit the false discovery rate
(FDR) of the resulting clusters to q(FDR)=0.05.
To create a robust and generalizable prediction model, the subject-specific contrast images
were used in a nested cross-validation analysis that ensured separation between training and
testing data (procedure schematized in eFigure 1). Prediction analysis was performed using
scikit.learn40 and its significance was assessed using an approximate permutation test.41
RESULTS
TREATMENT RESPONSE AND PREDICTION FROM INITIAL SEVERITY
Patients’ LSAS scores after CBT were reduced significantly (t38= 14.13; P <.001) (eTable
1). The reductions occurred for both LSAS subscales (fear: t38 = 11.76; P <.001; avoidance:
t38=13.94; P <.001) but were significantly greater for the avoidance than the fear sub-scale
(t38=4.04; P <.001).
The LSAS-pre was positively and significantly (r=0.37) correlated with LSAS-change (the
difference between LSAS-pre and LSAS-post) (Figure 2A), accounting for approximately
12% of the variance in treatment response (adjusted R2=0.1162; P=.02). The LSAS-pre
scores were similar for the D-cycloserine and placebo groups (F1,37=0.08; P =.77), and there
was a trend for greater improvement in the D-cycloserine group (F1,37=3.02; P =.09).
Adding the interaction of treatment group and LSAS-pre to the regression analysis explained
an additional 8% of variance (adjusted R2=0.20; P=.01), and this increase was significant
(F1,37=4.63; P <.04). The addition of other potentially relevant parameters such as sex,
initial depression scores (from the Montgomery-Åsberg Depression Rating Scale), and the
presence or absence of comorbid anxiety disorders to the regression analysis did not
significantly change the amount of explained variance (adjusted R2=0.21; P <.05).
This model was built and tested on the same data, but it is uncertain how the model would
generalize to new patients. To more accurately estimate the predictive power of the model,
we used a stratified cross-validation procedure (maintaining equal numbers of placebo and
D-cycloserine patients in each training set) that builds and tests models on independent
subsets of data. This more conservative, but generalizable, approach yielded a significant
decrease in explained variance (adjusted R2=0.13 vs 0.20 in the earlier-mentioned model;
P=.01 from approximate permutation test) (Figure 2B).
REGRESSION ANALYSES WITH BRAIN RESPONSES
Patients exhibited widespread brain responses to angry vs neutral faces, especially in
occipital and ventral temporal regions, and, to a lesser degree, in subcortical structures
(eFigure 3). We regressed LSAS-change on the contrast of angry vs neutral faces.
Covariates to control for initial severity (LSAS-pre) and treatment group (D-cycloserine or
placebo) were included in this whole-brain regression analysis (“Methods” section and
eAppendix).
Greater treatment response correlated significantly with greater pretreatment activation in 2
clusters of activation that both survived topological FDR correction at q(FDR)=0.05 (Figure
3 and eTable 3). The larger of these clusters extended across the right cuneus, superior
occipital gyrus, and posterior aspects of the middle temporal gyrus (Figure 3A). A second
cluster was located more ventrally on the right lateral cortical surface of the middle occipital
gyrus extending into the inferior temporal gyrus (Figure 3B). Because of their locations in
more superior and more inferior portions of the occipitotemporal cortex, we refer to these
clusters as the dorsal and ventral occipitotemporal cortex, respectively. The relation between
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the magnitudes of activation and LSAS-change and LSAS-pre is shown in Figure 3C and D.
Neither cluster correlated significantly with LSAS-pre (all P >.26).
Several additional clusters exhibited substantial correlations with LSAS-change but did not
survive the correction for multiple comparisons (eTable 3), including clusters in the right
dorsolateral and right and left ventrolateral prefrontal cortex. No correlation with LSAS-
change was found in either the left or right structurally defined amygdala42 (eAppendix and
eFigure 4). Adding the amygdala responses from each condition to a multiple regression
model including LSAS-pre and group information did not result in a significant prediction of
LSAS-change (multiple R2=0.43; adjusted R2=−0.02; P=.53) and did not significantly differ
from a model that only included LSAS-pre and group information.
To examine for the category selectivity of these effects, regression analysis was performed
for LSAS-change and the contrast of emotional vs neutral scenes. Despite robust and
widespread activation for emotional relative to neutral scenes (eFigure 5), this regression
analysis did not reveal any clusters at the same threshold as for the face contrast. The same
was true for a regression analysis with the intensively negative scenes, which were more
negative and more arousing than the angry faces, vs neutral scenes. Thus, the association
between pre-treatment activation and treatment response was selective for face stimuli.
NESTED CROSS-VALIDATION ANALYSIS
The above analyses revealed that consideration of initial (pretreatment) LSAS score and
group (placebo or D-cycloserine) accounted for 20% of treatment outcome variance
(adjusted R2=0.20; P=.01). The addition of neuroimaging (activation values) in the 2
occipitotemporal regions resulted in an improved accounting of 57% of the variance
(adjusted R2=0.57; P <.001). However, selecting clusters using multiple regression on the
entire data for model creation biases its predictions43 and makes uncertain its
generalizability. Therefore, using a nested cross-validation approach, we performed an
analysis creating a prediction model that separated, for each calculation, the training data set
that created the model and the test of that model on an independent data set (see eAppendix
for details). The correlation between actual and predicted treatment response using this
method was r=0.64, which corresponds to 41% of explained treatment outcome variance
(adjusted R2=0.41; P=.005 from approximate permutation test) (Figure 4). Using the same
prediction analysis that separates training and test data, the combination of LSAS-pre and
group accounted for 12% of the variance (adjusted R2=0.12; P=.01). As would be expected,
the use of a prediction model lowered the accounted for variance in all analyses, but
inclusion of the neuroimaging data tripled the amount of variance accounted for in treatment
outcome. The cross-validated neuroimaging-based model performed significantly better than
the cross-validated LSAS-pre model (Wilcoxon test of mean square errors: z=44; P <.04, 1-
tailed).
COMMENT
To our knowledge, the present study is the first to apply neuroimaging-based treatment
response prediction to patients with SAD. Pretreatment brain responses for angry vs neutral
faces in 2 occipitotemporal brain regions were significantly and positively associated with
CBT outcome. The neuroimaging measures in combination with pretreatment severity
scores (LSAS-pre) predicted CBT outcome significantly better, accounting for about 40% of
the variance in treatment response, than predictions based on LSAS-pre alone, which
accounted for about 12% of the variance in treatment response.
Pretreatment disorder severity has previously been suggested to be a predictor of treatment
outcome44 and this was the case in the present study. However, treatment prediction that
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additionally included neuromarkers substantially outperformed predictions based on
conventional clinical measures alone. Further, our findings suggest that the specifically
social nature of the face stimuli was relevant to their predictive value because activations to
emotional scenes, although extensive and robust, did not predict treatment outcome. Finally,
even when controlling for several potentially relevant factors, such as initial severity of SAD
and whether patients received D-cycloserine or placebo in addition to CBT, the predictive
power of the brain activations remained significant.
COGNITIVE NEUROSCIENCE OF TREATMENT RESPONSE PREDICTION IN SAD
The specific pattern of functional brain responses that predicted treatment response had both
expected and unexpected aspects. The finding that functional brain responses to faces (angry
vs neutral) but not scenes (negative vs neutral) predicted treatment response, despite the
equating of faces and scenes for emotional valence and arousal, is consistent with the
specifically social basis of SAD. However, the locations of activations that predicted
response were not the regions most consistently reported in studies comparing brain
responses in patients with SAD and typical control groups, such as the amygdala and other
limbic areas.24,45 In the present study, even when using a specific region of interest, no
association with treatment response was found in the amygdala despite its robust activation
to all experimental conditions. This may be consistent with a prior study reporting no
abnormality in the amygdala response to angry faces in SAD.46 Furthermore, although the
amygdala is important for affect, there is evidence for multiple pathways for affective
processing with little or no contribution of the amygdala.47 Consistent with the present
findings, 1 study found that in healthy participants processing of angry faces was associated
with increased effective connectivity from inferior occipital to ventrolateral prefrontal
regions, bypassing the amygdala.48
Multiple neuroimaging studies have reported differences between SAD and control groups
in similar visual regions for responses to emotional faces, although these cortical activation
differences have not received as much attention as the limbic differences.49,50 Further,
connectivity between higher-order visual areas and limbic areas is altered in SAD.51 In
relation to treatment, changes in both higher-order visual and limbic areas correlated with
effects of behavioral52,53 and pharmacological54 interventions in SAD. All these studies
reported increased activations after treatment, particularly in occipital and temporal regions,
in response to anxiety-provoking stimuli. In our study, greater activation in these regions
prior to treatment predicted greater treatment effects. Therefore, the high-order visual
cortical regions, where activation predicted CBT response in our sample, are implicated in
both basic and treatment studies of brain dysfunction in SAD.
Activations in 3 prefrontal cortical regions were also related to treatment outcome, although
not significant after correction for multiple comparisons. These pre-frontal regions are
associated with emotion regulation.55 The ventrolateral prefrontal cortex has also exhibited
differential activations in patients with SAD for faces with negative emotional
expressions.24 Thus, activation of this region could be predictive for treatment response
because of its role in stimulus reappraisal and selection of appropriate emotion regulation
strategies, which might be dysfunctional in SAD.28
POSSIBLE MECHANISMS RELATING IMAGING AND CLINICAL OUTCOME FINDINGS
The specific finding that greater response to angry relative to neutral faces in high-order
visual cortices predicts clinical response to CBT can be related to prior findings about SAD.
Patients with SAD display reduced activation in similar occipital clusters (along with
additional temporal, parietal, and frontal clusters) during emotion regulation tasks on
disapproving face stimuli.28 A fundamental goal of CBT is to enhance emotion regulation in
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SAD, so perhaps CBT was particularly successful in patients with superior emotion
regulation capacities, which was correlated with already stronger responses to angry faces in
visual regions. Thus, patients with particularly low responses to angry faces (even less than
for neutral faces) might have benefited less from treatment because of poorer emotion
regulation capacities. This interpretation is consistent with findings in mood disorders, such
as major depressive disorder, where activation changes in occipital cortices were found after
CBT13 and pharmacological treatment56 and where the rate of change in treatment
correlated with gray matter density in occipital regions.14
Most salient to SAD are the observations that, by electrophysiological measures, patients
with SAD show abnormally reduced attentional enhancement of visual regions similar to the
ones reported in the present article,57 which may reflect avoidance of angry faces.58 Based
on these findings, a behavioral treatment approach for SAD that yields clinical benefits59
has been attention retraining, in which patients are specifically trained to reallocate their
attention to faces. An fMRI study in healthy participants found that a comparable
experimentally induced modification of attentional bias to threatening faces was associated
with activation changes in a brain region similar in location to our ventral occipitotemporal
cortex cluster60 (without measureable changes in limbic regions). Furthermore, changes in
clinical measures of SAD induced by another cognitive-behavioral intervention, a
mindfulness-based stress-reduction program, were associated with activation increases
during emotion regulation also in occipital regions implicated in attentional deployment.53
Overall, these findings suggest that attentional mechanisms related to visual perception of
social stimuli may be mediated, in part, by activation of occipitotemporal regions and that
the status of these mechanisms prior to treatment is important in determining whether CBT
is an effective treatment for a patient with SAD.
CLINICAL IMPLICATIONS AND LIMITATIONS OF NEUROMARKERS PREDICTING
TREATMENT RESPONSE IN SAD
Most prior imaging studies of SAD have focused on what brain differences are in common
among patients relative to controls, whereas the present study focused on variation among
patients that is relevant to treatment efficacy. By definition, analyses that focus on
homogeneity vs heterogeneity in SAD will reveal different brain regions. For example, the
scatterplots (Figure 3) show that patients with greater activation for angry than neutral faces
also gained greater benefits from CBT, whereas patients showing the reverse activation
(greater activation for neutral than angry faces) gained lesser benefits from CBT. A standard
analysis that combines these opposite patterns of activation by treating patients with SAD as
a homogenous group would find little or no activation in this region (although we found in
adjacent, nonoverlapping regions exactly such an increased response to angry vs neutral
faces for the patients as a group).
Conversely, an analysis of the kind reported here can provide a new avenue for the
identification of treatment-relevant subtypes in SAD that is based on brain measures and, to
a lesser extent, conventional clinical measures. In line with this reasoning, most studies
examining interventions to treat SAD6–8 considered patients as a single, homogeneous group
with no evidence as to whether a particular patient was more or less likely to benefit from
CBT or pharmacological treatment. However, in most treatment studies with either
modality, interventions were effective in only approximately half of the sample, with little
additional gain for combination treatment.7 Accordingly, there is a large demand for
evidence-based criteria to determine whether a patient should receive CBT or
pharmacotherapy to maximize treatment response. Neuroimaging may offer an evidence-
based path toward selection of optimal treatments, such that neuromarkers could selectively
identify which patients are most likely to benefit from which treatment option. An
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integration of neuromarkers with genetic, behavioral, and other biomarkers is likely to
further refine the prediction for individual patients61–63
Neuroimaging studies of SAD and other neuropsychiatric disorders have identified brain
differences in these disorders, but these observations have had limited clinical implications
so far. Neuromarkers may become a practical clinical tool to guide the selection of optimal
treatments for individual patients. However, several limitations of the present study would
need to be addressed in further studies before such practical application is possible. First,
although we used analytic methods that prioritized generalizability (eg, cross-validation
techniques), a larger study is needed in which a model derived from a particular group is
applied to a completely independent group to determine the true model generalizability.
Second, although statistically it appeared to make no difference, a larger study would not
divide patients into drug and placebo groups. Third, it is unknown whether fMRI activation
to angry vs neutral faces is the optimal neuromarker. Perhaps other facial expressions (eg,
disgust or fear), or multimodal combinations of functional and structural measures, may be
better predictors. Fourth, direct comparison of participants with SAD and typical
participants would be useful in determining the typical pattern of activation in these
predictive brain areas and may reveal the patho-physiological mechanism related to
prediction (eg, whether these areas typically do or do not have activations greater for angry
than neutral faces). Fifth, it will be essential to perform studies that contrast alternative
treatments and thus discover whether neuromarkers can differentially predict which
treatment is optimal for a patient. The positive finding that neuromarkers predicted treatment
outcome significantly better than currently used clinical scales for SAD, however, provides
evidence that treatment selection for a patient with SAD can move toward evidence-based
neurobiological approaches that may guide toward optimal, individualized clinical benefits.
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Figure 1.
The functional magnetic resonance imaging task. A, Examples of stimuli for each category
and color code. B and C, Visualization of stimulation blocks that cycled through all 5
experimental conditions, block timing within a block, and visualization of stimulus (S)
timing within a block.
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Figure 2.
Relation and prediction using Liebowitz Social Anxiety Scale30 (LSAS) scores. A, Relation
of initial social anxiety disorder severity score (LSAS-pre) to treatment effectiveness
(change in LSAS score [LSAS-change]). D indicates D-cycloserine; and P, placebo. Left
and bottom panels of part A: box plots of LSAS-change and LSAS-pre for each group. B,
Relation between predicted LSAS-change from cross-validated model and actual LSAS-
change using LSAS-pre and group information only.
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Figure 3.
Two right-hemisphere occipitotemporal regions in which initial activation for angry vs
neutral faces significantly predicted treatment effectiveness. A and B, t Values and locations
of clusters showing positive relations with change in Liebowitz Social Anxiety Scale30
scores (LSAS-change). C, Cluster activation means of each participant vs LSAS-change.
Right panel of parts C and D: box plots of cluster means grouped by treatment group (D
indicates D-cycloserine; P, placebo) showing similar results in both groups. D, Cluster
activation means vs initial LSAS scores (LSAS-pre) showing no significant relation. Color
bar represents t values.
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Figure 4.
Results from the prediction model created via nested cross-validation using Liebowitz Social
Anxiety Scale30 (LSAS) scores, group information, and brain imaging data. A, Relation
between predicted change in LSAS score (LSAS-change) using this model and actual
LSAS-change. B, Approximate permutation test results: null distribution (gray), actual value
(red). C, Voxels selected in at least 1 fold of the cross-validation. Color bar indicates the
number of folds in which a particular voxel was selected.
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